Abstract:That cancer cells show patterns of metabolism different from normal cells has been known for over 50 years. Yet, it is only in the past decade or so that an appreciation of the benefits of these changes has begun to emerge. Altered cancer cell metabolism was initially attributed to defective mitochondria. However, we now realize that most cancers do not have mitochondrial mutations and that normal cells can transiently adopt cancer-like metabolism during periods of rapid proliferation. Indeed, an encompassing, albeit somewhat simplified, conceptual framework to explain both normal and cancer cell metabolism rests on several simple premises. First, the metabolic pathways used by cancer cells and their normal counterparts are the same. Second, normal quiescent cells use their metabolic pathways and the energy they generate largely to maintain cellular health and organelle turnover and, in some cases, to provide secreted products necessary for the survival of the intact organism. By contrast, undifferentiated cancer cells minimize the latter functions and devote their energy to producing the anabolic substrates necessary to maintain high rates of unremitting cellular proliferation. Third, as a result of the uncontrolled proliferation of cancer cells, a larger fraction of the metabolic intermediates normally used by quiescent cells purely as a source of energy are instead channeled into competing proliferation-focused and energy-consuming anabolic pathways. Fourth, cancer cell clones with the most plastic and rapidly adaptable metabolism will eventually outcompete their less well-adapted brethren during tumor progression and evolution. This attribute becomes increasingly important as tumors grow and as their individual cells compete in a constantly changing and inimical environment marked by nutrient, oxygen, and growth factor deficits. Here, we review some of the metabolic pathways whose importance has gained center stage for tumor growth, particularly those under the control of the c-Myc (Myc) oncoprotein. We discuss how these pathways differ functionally between quiescent and proliferating normal cells, how they are kidnapped and corrupted during the course of transformation, and consider potential therapeutic strategies that take advantage of common features of neoplastic and metabolic disorders.

Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat

Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers

Regulation of cancer metabolism by O-GlcNAcylation

The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues

MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities

Targeting MYC at the intersection between cancer metabolism and oncoimmunology

Dysregulated metabolism contributes to oncogenesis

Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression

MYC on the Path to Cancer

Regulatory Role of Cancer Microenvironment in Cancer Metabolism

Targeting oncogenic Myc as a strategy for cancer treatment

The MYC oncogene — the grand orchestrator of cancer growth and immune evasion

Transcriptional regulation by MYC: an emerging new model

Cancer metabolism and carcinogenesis

Regulation of lipid and serine metabolism by the oncogene c-Myc

Metabolic reprogramming in cancer: Mechanisms and therapeutics

MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers

Altered metabolism in cancer: insights into energy pathways and therapeutic targets

MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis

The role of ubiquitination and deubiquitination in cancer metabolism

C‐myc–impdh1/2 Axis Promotes Tumourigenesis by Regulating GTP Metabolic Reprogramming